YB Urban Renewal Residential Development Ltd, formerly known as Cannassure Therapeutics Ltd, is an Israel-based urban renewal company. The Company is engaged mainly in urban renewal projects. In the urban renewal projects sector, the Company partakes in activities that aim to clear out areas of inner cities deemed to be neglected, unused and loosely maintained, in favor of new multifamily housing, business areas, as well as other developments improving the city landscape. The Firm aims to achieve economic, cultural and environmental renewal of the neglected inner city areas. The Company cooperates with a range of specialists in the field of urban renewal with knowledge and experience in urban planning and construction work.

Employees

Sector

Real Estate Development & Operations

More about the company

Market Cap	2.84Cr 94.06L 81.14L 76.32L 69.53L 1.31Cr 89Cr 1.31Cr 9.02Cr 3.51Cr 45Cr 3.53Cr 3.45Cr 150.57Cr	P/E 2024	-4.93x	P/E 2025	-9.22x
Enterprise Value	2.85Cr 94.44L 81.47L 76.63L 69.81L 1.31Cr 90Cr 1.32Cr 9.06Cr 3.53Cr 46Cr 3.55Cr 3.47Cr 151.18Cr	EV / Sales 2024	376x	EV / Sales 2025	-
Free-Float	54.18%	Yield 2024 *	-	Yield 2025	-

31/08	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04/05	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03/05	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
13/11	Y.B Urban Renewal - Residential Development Ltd announced that it expects to receive ILS 0.53001 million in funding	CI
10/25/10	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
01/24/01	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
11/24/11	Cannassure Therapeutics Ltd will Change its Name to Y.B URBAN RENEWAL - RESIDENTIAL DEVELOPMENT LTD	CI
28/24/28	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
27/24/27	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
31/23/31	Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/23/27	Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/21/09	Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority	CI

26/21/26	DanCann Pharma A/S : publishes Year-end report for 2020	AQ
18/21/18	Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology	AQ
18/21/18	Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology	AQ
15/20/15	DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)	AQ
19/20/19	Lipidor : publishes interim report for Q3 2020	AQ

Manager	Title	Age	Since
Ada Bar Kama CEO	Chief Executive Officer	56	31/03/2022
Oren Attiya DFI	Director of Finance/CFO	45	-
Daniel Shapira AUD	Comptroller/Controller/Auditor	72	26/06/2019

Director	Title	Age	Since
Nir Peles CHM	Chairman	53	09/12/2021
Shimon Bar-Kama BRD	Director/Board Member	74	04/12/2018
Varda Kalal BRD	Director/Board Member	58	14/02/2022

Cannassure Therapeutics Ltd Share Price TEL AVIV STOCK EXCHANGE

Stocks

CSURE

IL0001110134

Real Estate Development & Operations

Valuation : Cannassure Therapeutics Ltd

Latest news : Cannassure Therapeutics Ltd

Press Releases : Cannassure Therapeutics Ltd

Quotes and Performance

Managers and Directors : Cannassure Therapeutics Ltd

Other Real Estate Development & Operations

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANNASSURE THERAPEUTICS LTD	-7.54%	-22.20%	-	-	94.06L
MITSUBISHI ESTATE CO., LTD.	-1.77%	-0.26%	+17.50%	+94.79%	2.89TCr
EMAAR PROPERTIES	-1.66%	-3.27%	-25.59%	+49.23%	2.6TCr
MITSUI FUDOSAN CO., LTD.	-2.57%	-0.33%	-4.24%	+36.16%	2.61TCr
ALPHA DHABI HOLDING	-2.80%	-5.19%	-33.52%	-63.46%	2.04TCr
SUMITOMO REALTY & DEVELOPMENT CO., LTD.	-2.74%	-2.88%	+7.13%	+67.05%	1.96TCr
DLF LIMITED	-0.24%	+0.16%	-10.76%	+31.07%	1.76TCr
HONGKONG LAND HOLDINGS LIMITED	+1.50%	-0.85%	+27.87%	+129.38%	1.71TCr
ALDAR PROPERTIES	-1.57%	-3.83%	-20.65%	+42.88%	1.64TCr
AZRIELI GROUP LTD.	+0.15%	+1.24%	+27.97%	+95.78%	1.6TCr
Average	-1.92%	-0.47%	-1.59%	+53.65%	2.09TCr
Weighted average by Cap.	-1.46%	-0.19%	-2.23%	+53.01%

	2024	2025
Net sales	76T 25.14T 21.69T 20.4T 18.59T 34.95T 23.86L 35.14T 2L 93.87T 12.14L 94.4T 92.35T 40.25L	-
Net income	-36.75L -12.16L -10.49L -10L -9L -16.9L -12Cr -16.99L -1.17Cr -45.39L -5.87Cr -45.65L -44.66L -19Cr	-29.96L -10L -9L -8L -7L -13.78L -9.41Cr -13.85L -95.07L -37L -4.78Cr -37.21L -36.41L -16Cr
Net Debt	10L 3L 3L 3L 2L 5L 3.08Cr 5L 31.1L 12.1L 1.57Cr 12.17L 11.91L 5.19Cr	1L 38.04T 32.82T 30.87T 28.12T 52.88T 36.11L 53.17T 4L 1L 18.37L 1L 1L 60.9L